Evidence map›Paper›PMID 36245635›Full record

ArticleJournal of thoracic disease2022

Improving outcomes in malignant pleural mesothelioma in an integrated health care system.

Stephanie Ossowski, Yun-Yi Hung, Kian Banks, Diana Hsu, Lisa Herrinton, Simon Ashiku, Ashish Patel, J Marie Suga, Jeffrey B Velotta

Open access · diamondAbstract read
In one paragraph

Article in Journal of thoracic disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Stephanie OssowskiDepartment of Hematology/Oncology, Kaiser San Francisco Medical Center, San Francisco, CA, USA.
Yun-Yi HungDivision of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
Kian BanksDepartment of Thoracic Surgery, Kaiser Oakland Medical Center, Oakland, CA, USA.
Diana HsuDepartment of Thoracic Surgery, Kaiser Oakland Medical Center, Oakland, CA, USA.
Lisa HerrintonDivision of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
Simon AshikuDepartment of Thoracic Surgery, Kaiser Oakland Medical Center, Oakland, CA, USA.
Ashish PatelDepartment of Thoracic Surgery, Kaiser Oakland Medical Center, Oakland, CA, USA.
J Marie SugaDepartment of Oncology, Kaiser Vallejo Medical Center, Vallejo, CA, USA.
Jeffrey B VelottaDepartment of Thoracic Surgery, Kaiser Oakland Medical Center, Oakland, CA, USA.
Kaiser Permanente Oakland Medical Center · USKaiser Permanente · USKaiser Permanente San Francisco Medical Center · USKaiser Permanente Vallejo Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor that should be managed by an experienced surgical and multidisciplinary group. Our objective was to determine the impact of proficient surgeons and MPM bi-disciplinary review on outcomes of patients with MPM. Methods: Through this cohort study, electronic medical records of 368 adult patients with MPM from 1/1/2009 to 12/31/2020 were reviewed and compared before and after MPM surgeries were regionalized to specialized surgeons and bi-disciplinary review of MPM patient treatment options. We used the Kaplan-Meier method and log-rank tests to compare survival rates by period, by treatment type, and by stage. Patients were followed from cancer diagnosis date until they died or end of study follow-up, whichever occurred first. We also conducted Cox proportional hazards regression model to examine the overall survival (OS) with adjustments for age, histology, stage, and Charlson comorbidity index (CCI). Results: Despite similar staging, more patients received any MPM directed treatment from 2015-2020 compared with those patients from 2009-2014. Specifically, there was an increase in patients who received pleurectomy/decortication (PD) from 2015-2020 compared to those who received PD in 2009-2014. Patients with similar age, CCI, stage, and histology had an increase in OS of 12 months with multimodality therapy (surgery, systemic therapy, +/- radiation) compared to those patients who received no treatment. Conclusions: Consolidating mesothelioma surgery to a specialized surgical team and regular bi-disciplinary review of MPM cases to determine appropriate multimodality therapy, increases the incorporation of surgical treatments in the management of patients with MPM.

Indexed as

Malignant pleural mesothelioma (MPM)multimodality therapyoverall survival (OS)pleurectomy/decortication (PD)regionalization

Identifiers

PMID36245635
PMCPMC9562545
OpenAlexW4292683665

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.